Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News SCYNEXIS Inc SCYX

Healthcare
SCYNEXIS, Inc. is a biotechnology company. It is pioneering medicine to overcome and prevent difficult-to-treat and drug-resistant infections. It develops antifungal platform fungerps, a novel class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have generally shown in vitro and in vivo activity against a range of human fungal pathogens,... see more

Recent & Breaking News (NDAQ:SCYX)

SCYNEXIS to Present Clinical Data from Ongoing FURI and CARES Studies at the 10th Trends in Medical Mycology Meeting Showing Oral Ibrexafungerp Provides a Favorable Therapeutic Response in Patients with Severe Fungal Infections

GlobeNewswire October 7, 2021

Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2021

PR Newswire September 30, 2021

SCYNEXIS Presents Interim Analysis from FURI at Virtual IDWeek 2021 Showing Favorable Therapeutic Response in Severe Hospital-Based Fungal Infections Treated with Oral Ibrexafungerp

GlobeNewswire September 29, 2021

SCYNEXIS to Present Data on Oral Ibrexafungerp at IDWeek 2021 from Interim Analyses of Phase 3 FURI Clinical Trial Showing Therapeutic Response Rates in Patients with Mucocutaneous and Invasive Fungal Infections

GlobeNewswire September 23, 2021

SCYNEXIS Announces U.S. Availability of BREXAFEMME® (ibrexafungerp tablets), the First New Antifungal Class of Therapy Approved by the U.S. FDA for Vaginal Yeast Infections in More Than 20 Years

GlobeNewswire September 22, 2021

SCYNEXIS Announces Hansoh Pharma's Application to National Medical Products Administration (NMPA) in China for Phase 3 Trial of Ibrexafungerp for Treatment of Vulvovaginal Candidiasis (VVC)

GlobeNewswire September 13, 2021

SCYNEXIS to Participate in Upcoming Investor Conferences

GlobeNewswire September 8, 2021

SCYNEXIS Reports Second Quarter 2021 Financial Results and Provides Corporate Update

GlobeNewswire August 16, 2021

Acurx Pharmaceuticals Joins the Antimicrobials Working Group

PR Newswire August 5, 2021

SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire August 2, 2021

SCYNEXIS Announces Two Oral Presentations on Pooled Data from the BREXAFEMME (Ibrexafungerp tablets) Phase 3 VANISH Program Demonstrating Consistent Efficacy in the Treatment for Vaginal Yeast Infections at the IDSOG 2021 Virtual Annual Meeting

GlobeNewswire July 29, 2021

SCYNEXIS Announces Three Oral Presentations of Ibrexafungerp Demonstrating Clinical and In Vitro Activity Against Candida Species at the 31st ECCMID

GlobeNewswire July 12, 2021

SCYNEXIS to Present at Ladenburg Thalmann's Virtual 2021 Healthcare Conference

GlobeNewswire July 7, 2021

SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire July 2, 2021

SCYNEXIS to Present Commercial Launch Update for BREXAFEMME® (ibrexafungerp tablets)

GlobeNewswire June 23, 2021

SCYNEXIS to Present at the BIO Digital International Convention 2021

GlobeNewswire June 11, 2021

SCYNEXIS Confirms that BREXAFEMME® (ibrexafungerp tablets) Qualifies for 10 Years of Regulatory Exclusivity for Vaginal Yeast Infections

GlobeNewswire June 9, 2021

Crestone Joins Antimicrobials Working Group

PR Newswire June 8, 2021

SCYNEXIS Announces FDA Approval of BREXAFEMME® (ibrexafungerp tablets) as the First and Only Oral Non-Azole Treatment for Vaginal Yeast Infections

GlobeNewswire June 2, 2021

SCYNEXIS Reports First Quarter 2021 Financial Results and Provides Corporate Update

GlobeNewswire May 17, 2021